Dihexa
An angiotensin-IV-derived peptidomimetic investigated for synaptic and cognitive effects.
- Evidence grade
- DPreclinical Research
Preclinical Research
- Regulatory status
- Research Use Only
Not FDA-approved for human treatment or cognitive enhancement.
- Human data
- No
No registered clinical trials identified
- Last reviewed
- October 27, 2026
Overview
An angiotensin-IV-derived peptidomimetic investigated for synaptic and cognitive effects.
Not FDA-approved for human treatment or cognitive enhancement.
A retracted mechanism paper weakens commonly repeated explanations. There is no basis for a clinical enhancement protocol.
Why It's Being Studied
- Synaptic research
- Preclinical cognition
Mechanism of Action
Proposed neurotrophic signalling remains uncertain; a widely cited foundational HGF/c-Met mechanism paper was retracted and should not be treated as reliable confirmation.
Proposed neurotrophic signalling remains uncertain; a widely cited foundational HGF/c-Met mechanism paper was retracted and should not be treated as reliable confirmation. A retracted mechanism paper weakens commonly repeated explanations. There is no basis for a clinical enhancement protocol.
From molecular target to clinical evidence
Tap each stage to see what happens.
Background: Clinical Peptide Medicines
Clinical peptide medicines include endocrine treatments, antimicrobial drugs, receptor blockers and targeted diagnostic or cancer agents. They do not share one mechanism or one set of indications.
An approval belongs to a specific medicine and indication. A diagnostic tracer, an antibiotic and a hormone are not interchangeable wellness products; read each profile's own mechanism and prescribing source.
Research Areas & Routes Studied
- Synaptic research
- Preclinical cognition
- Animal and cell research
Evidence Summary
Evidence is preclinical; animal findings do not establish human cognitive or dementia benefits.
Higher tiers carry more weight. Filled tiers have evidence for Dihexa; tap to read it.
- Evidence is preclinical; animal findings do not establish human cognitive or dementia benefits.
2 cited sources.
- Animal study1
- In-vitro study1
Preclinical evidence
- Evidence is preclinical; animal findings do not establish human cognitive or dementia benefits.
Reported Adverse Events in Research
- Human administration safety and long-term effects are not established; growth-signalling hypotheses create unresolved concerns.
Limitations of Current Evidence
- A retracted mechanism paper weakens commonly repeated explanations. There is no basis for a clinical enhancement protocol.
- Findings apply to the product, route and population studied; they do not establish benefits or safety for unrelated wellness uses or research-vial products.
How to Read This Research
- Is this a single molecule or a family of medicines?
- Is the use diagnostic, therapeutic or investigational?
- Does the quoted outcome match the exact product, formulation and population?
- Use the compound-specific mechanism above; this diagram describes drug development, not a shared biological pathway.
- Historical approval, present availability and off-label use are distinct questions.
- For radiopharmaceuticals and hospital medicines, specialist handling is part of the treatment context.
- Indication
- The condition and population for which a medicine is approved.
- Antagonist
- A compound that blocks activity at a receptor.
- Radiopharmaceutical
- A medicine containing a radioactive isotope for imaging or treatment.
Compare With Other Compounds
| Dihexa | Trofinetide | |
|---|---|---|
| Evidence grade | D — Preclinical Research | B — Moderate Human Evidence |
| Regulatory status | Research Use Only | FDA Approved for Specific Indication |
| Human data | No | Yes |
| Clinical trials | None identified | Registered trials exist |
| Research routes | Animal and cell research | Oral approved medicine |
| Cited sources | 2 | 2 |
Frequently Asked Questions
Research References
- Animal study
Dihexa — animal study
- In-vitro study
Retracted foundational mechanism paper